BonAlive Biomaterials launches osteostimulative BonAlive putty
BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices, today announced the launch of a patented, ready-to-use and mouldable version of their osteostimulative BonAlive bioactive glass...
View ArticleBONESUPPORT launches new registry to collect data of CERAMENT™|G to protect...
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today the launch of a new...
View ArticleNew procedure helps curtail complication rate associated with bone grafting
UT Arlington and Texas Health Arlington Memorial Hospital are investigating whether bone grown from the body's own stem cells can replace traditional types of bone grafting.
View ArticleComprehensive fitness and nutrition regimens may prevent bone and muscle...
Being physically active may significantly improve musculoskeletal and overall health, and minimize or delay the effects of aging, according to a review of the latest research on senior athletes (ages...
View ArticleDiet may influence susceptibility to autoinflammatory bone disease in at-risk...
Diet-induced changes in the gut's bacterial ecosystem can alter susceptibility to an autoinflammatory bone disease by modifying the immune response, St. Jude Children's Research Hospital scientists...
View ArticleFDA grants QIDP and Fast Track designation to Nabriva's lefamulin for...
Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and...
View ArticleAntibiotic-resistant bacteria share resources to cause chronic infections,...
Antibiotic-resistant bacteria can share resources to cause chronic infections, Vanderbilt University investigators have discovered.
View ArticleAmgen's XGEVA (denosumab) receives FDA approval for treatment of...
Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate...
View ArticleActavis provides overview of standalone global pharmaceutical development...
Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth....
View ArticleNabriva Therapeutics completes $120 million Series B financing
Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and...
View ArticlePhysical exercises before and during pregnancy effective in reducing low...
Pregnancy changes a woman's body in different ways, including the muscles, ligaments, bones, and joints that make up the musculoskeletal system.
View ArticlePatients can be trained to safely self-administer long-term IV antibiotics,...
Uninsured patients can be trained to safely and efficiently self-administer long-term intravenous antibiotics, UT Southwestern Medical Center physicians have found, a result that may have profound...
View ArticleStudy shows impact of increasing number of opioid-related hospitalizations on...
Infection is a serious complication of intravenous drug abuse and a major cause of illness and death among intravenous drug users. As the national problem of opioid abuse, including of heroin,...
View ArticleBacterial blood infection more likely to kill women within 30 days
Clinicians around the world have long suspected that bacteraemia due to Staphylococcus aureus has a worse outcome in women compared to men, but direct evidence has been elusive.
View ArticleSilver ion-coated biocompatible scaffolds could combat MRSA while...
Methicillin-resistant Staphylococcus aureus (MRSA) infections are caused by a type of staph bacteria that has become resistant to the antibiotics used to treat ordinary staph infections.
View ArticleFDA grants QIDP and Fast Track designation to Nabriva's lefamulin for...
Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and...
View ArticleAntibiotic-resistant bacteria share resources to cause chronic infections,...
Antibiotic-resistant bacteria can share resources to cause chronic infections, Vanderbilt University investigators have discovered.
View ArticleAmgen's XGEVA (denosumab) receives FDA approval for treatment of...
Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate...
View ArticleActavis provides overview of standalone global pharmaceutical development...
Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth....
View ArticleNabriva Therapeutics completes $120 million Series B financing
Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and...
View Article
